Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I don't feel that AS has returned any value for LTHs , I haven't seen any near term inflection points or starts of value curves. The SP was a 39.99 on 9th April 2020.
We have a CEO that repeatedly writes cheques that he cannot cash.
My issue is with the man at the top not the science or the operation.
You are happy with AS behind the steering wheel and I'm not. Nothing either of us say will change the others view .
Time will tell which one of us was right.
Again no one here will complain when AVA6000 gets approved by the FDA.
the company has told investors for years it had a long list of potential drugs it could potentially licence precision for…… none have eventuated, despite sitting on data since mid to late 2022 that showed the company precision was working.
the company had £60m quid from the cln in october 2022! it got ****ed up the wall on some hairbrained idea to go on a diagnostics buying spree when valuations post covid overvalued the businesses.
there are many ways this latest valuation and fundraise of the company at 50p could have been avoided but management and the board ****ed it up.
there are also plenty of companies that get drugs approved that go onto destroy shareholder value through company mismanagement and commercial inexperience …. stx anyone? getting the leadership right now is essential imo.
as is not ceo calibre for a company with the opportunity to change the landscape of oncology for high fap tumours.
Just got my average down to 66p
Not sure if this is a good or bad thing
"Why do you think this isn’t actually the correct strategy for the LTH"
Because you need to divorce the company from the Share Price.
This is an investment. Go work for AVCT if you just love the science.
Say, just say, the SP falls to 40p. It could easily be bought out at 120p and then BP runs with it. How would that work for the LTH?
This blinkered outlook to potential scenarios is quite something.
“ I cannot knock your positivity but it’s impossible for me to ignore what has happened.”
Why do you think this isn’t actually the correct strategy for the LTH. If they can get this approved phase 2 solo and partner at way premiums for the platform than before phase 2, you might find the 19% dilution was a good deal. We don’t know the circumstances data or cost benefit analysis done on future deals rather than doing deals phase 1.
Can only but agree with MD2020 - AS has to go - plus CFO. I see SP has just crashed through 50p - what a nightmare this raise has caused for LTH's - the latest in a now long series of Smith debacles.
I cannot knock your positivity but its impossible for me to ignore what has happened.
AS clattered every hurdle with LFT and we are seeing more of the same.
I'm sure he has good people working for him but the buck stops with him, he is the CEO not Simon.
I personally believe it needs change, if not we have years more of the same - shambolic commercial decisions, armature comms. If you are happy with everything as it is , fine but I personally would like a safer pair of hands.
Yeah our NEW European health fund and NEW USA institutional investors (40 day black out) forward sold. True some institutions on the placing took advantage of forward selling on the drop from 130 however it won’t have been all of them, also it wouldn’t have been significant amounts as no TR1s were RNS’d.
“The science “working” is only half the battle, you need the structure and commercial know how to bring it to fruition.”
You don’t think Simon can bring this to fruition and get AVA6000 approved? The short term share price is irrelevant on the above. The institutions invested 26 million at 50p for the longterm commercial success of Avacta, don’t get long term investment opportunities, confused by the short term volatility of the market.
@Icecool.... "Institutional investors don’t pony up 26 million plus on blind faith when the interest rate at the moment is pretty attractive"
They do when they can forward sell most of them and make up to 50% profit
Ice.
And yet here we are.
It doesn't matter what either of us think or hope this might be worth, the market doesn't see it the same way.
Until there is a clear explanation as to why the £26m plus and a 50p SP was a better than "optionality, no dilutive funding, spin DX, don't worry, nudge and wink" it's understandable why Simon's CV alone isn't enough to move things in the right direction.
@Morris
Sorry but we have hired a commercial lead for therapeutics. He’s pretty experienced.
“Simon has over 26 years' commercial experience in the biopharma industry. He has worked with companies from large and mid-sized pharma such as Bristol-Myers-Squibb and Menarini Group to early stage biotechs, supporting business development and licensing activities in addition to being involved in all aspects of business and corporate development. Simon has been involved in over 80 commercial deals across Europe, North America, Australasia, Japan, Russia/CIS and South America”
Institutional investors don’t pony up 26 million plus on blind faith when the interest rate at the moment is pretty attractive.
The science “working” is only half the battle, you need the structure and commercial know how to bring it to fruition.
AS is seen as AVACTA, his reputation is tarnished, he is commercially incompetent and therefore the brand and trust is damaged.
As Myles said, management and board have managed to mess things up over the last 4 years. Alastair has very little credit in the bank. His track record is of promising much and delivering little.
It feels like blind faith to believe that, this time he has something up his sleeve and can be trusted as a pair of safe hands to effectively and efficiently navigate the business to success.
Other than those looking for a quick profit, who is going to invest long term when the CEO’s word cannot be believed .
It needs a change at the top, a rebrand.
Yes more revenue, possibly less cost per standard dose period as you're not dealing with side effects as well, with all of their specialties and drugs. But one of the reasons that the dox has a limited revenue per patient is that they die.
More cycles and a larger TAM due to less toxicity means more revenue potential
Sorry to sound callous but if patients take it for longer does that mean more profit for avacta?
Also, if the person with the 65% tumour reduction (3rd cohort) has been able to continue treatment he will have had AVA6000 for 15 months (most with normal dox 6 cycles or 4.5 months) and without the awful side effects. There were also several patients receiving drug beyond the usual 4.5 months so I am sure more superb stories of patients lives being extended and with much better quality of life. Hopefully 2 weekly dosing will smash it out of the park given first line treatment where possible too.
Shareholders won’t be complaining, when the FDA eventually approves AVA6000.
1. No MTD found.
2. Biopsy data has shown proof of platform mechanism.
3. Dox kills cancer cells (been established since the 1960s)
4. Deemed safe at 3.5 times the normal standard dose of Dox. With no dose limiting side effects.
Remember why you invested in Avacta in the first place. Have a great day. 💯😊👍